X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.25.

A number of equities research analysts have recently commented on the company. Leerink Partners initiated coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Wells Fargo & Company began coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target for the company. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th.

Insider Activity

In related news, President John Volpone sold 24,576 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $109,117.44. Following the transaction, the president directly owned 265,305 shares in the company, valued at approximately $1,177,954.20. This trade represents a 8.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Adam R. Craig sold 47,436 shares of X4 Pharmaceuticals stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the transaction, the chairman owned 328,651 shares in the company, valued at $1,459,210.44. This trade represents a 12.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 80,555 shares of company stock valued at $356,126 over the last 90 days. 1.13% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its position in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after acquiring an additional 9,690 shares during the period. SummitTX Capital L.P. bought a new position in shares of X4 Pharmaceuticals during the 1st quarter worth about $46,000. Pettinga Financial Advisors LLC bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter worth about $47,000. Two Sigma Investments LP acquired a new position in shares of X4 Pharmaceuticals during the third quarter valued at about $47,000. Finally, Squarepoint Ops LLC acquired a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at about $50,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Up 2.9%

X4 Pharmaceuticals stock opened at $3.50 on Friday. X4 Pharmaceuticals has a 52 week low of $2.80 and a 52 week high of $4.83. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The stock has a market cap of $347.02 million, a price-to-earnings ratio of -2.92 and a beta of 0.39. The company’s 50-day moving average price is $4.02 and its two-hundred day moving average price is $4.03.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.The firm had revenue of $8.81 million during the quarter, compared to the consensus estimate of $2.42 million. On average, analysts expect that X4 Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Key Stories Impacting X4 Pharmaceuticals

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Oversold conditions may support a rebound: XFOR has fallen 20.8% over the past four weeks, and Zacks says the stock is now technically oversold. The analysis suggests selling pressure may be losing momentum, while upward earnings-estimate revisions could help trigger a trend reversal. X4 Pharmaceuticals Loses 20.8% in 4 Weeks
• Positive Sentiment: Several near-term earnings forecasts improved: Brookline raised its 2026 full-year EPS estimate to a loss of $0.71 from $0.79, its 2027 estimate to a loss of $0.90 from $0.95, and its Q3 and Q4 2026 estimates to losses of $0.20 and $0.25, respectively. These revisions point to somewhat better expected profitability in the near term. Brookline Capital Markets XFOR Estimates
• Neutral Sentiment: Reported short-interest data is inconclusive: The report lists short interest at zero shares as of September 10, unchanged from the prior period, implying no measurable short-selling pressure. However, the figures appear anomalous and provide little actionable insight.
• Negative Sentiment: Long-term earnings expectations were reduced: Brookline cut its FY2028 EPS forecast to a loss of $1.29 from $0.26 and its FY2029 forecast to a loss of $0.15 from $0.99. Its FY2030 estimate also fell to $2.86 from $3.29, signaling greater uncertainty about the timing and scale of X4’s eventual profitability. Brookline Capital Markets Long-Term XFOR Estimates

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.